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Abstract
The α7nicotinic receptor (nAChR) is a major subtype of the nAChRs in the central nervous
system, and the receptor plays an important role in brain function. In the dbSNP database,
there are 55 single nucleotide polymorphisms (SNPs) that cause missense mutations of the
human α7nAChR in the coding region. In this study, we tested the impact of 14 SNPs that
cause missense mutations in the agonist binding site or the coupling region between bind-
ing site and channel gate on the receptor function. The wild type or mutant receptors were
expressed or co-expressed in Xenopus oocytes, and the agonist-induced currents were
tested using two-electrode voltage clamp. Our results demonstrated that 6 mutants were
nonfunctional, 4 mutants had reduced current expression, and 1 mutants altered ACh and
nicotine efficacy in the opposite direction, and one additional mutant had slightly reduced
agonist sensitivity. Interestingly, the function of most of these nonfunctional mutants could
be rescued by α7nAChR positive allosteric modulator PNU-120596 and agonist-PAM
4BP-TQS. Finally, when coexpressed with the wild type, the nonfunctional mutants could
also influence the receptor function. These changes of the receptor properties by the muta-
tions could potentially have an impact on the physiological function of the α7nAChR-medi-
ated cholinergic synaptic transmission and anti-inflammatory effects in the human SNP
carriers. Rescuing the nonfunctional mutants could provide a novel way to treat the related
disorders.
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Introduction
Cholinergic transmission plays an important role in brain function, such as learning and mem-
ory through the neurotransmitter acetylcholine and its receptors [1]. nAChRs are acetylcho-
line-operated ion channels. They belong to the pentameric ligand-gated ion channel
superfamily, which includes vertebrate cation-selective nicotinic receptors [2], serotonin recep-
tor type 3 [3] and zinc-activated ion channel [4], and anion-selective GABAA/C receptors [5–7]
and glycine receptors [8]. The pentameric ligand-gated ion channels are allosteric proteins [9],
in which, the orthosteric ligand binding sites are located in the extracellular N-terminal
domain, and the ion conducting channel is formed by the transmembrane domain. The bind-
ing site is formed by 6 binding loops. Loops A, B, C from one subunit forms the principal side
of the binding pocket, whereas loops D, E, F from the neighboring subunit form the comple-
mentary side of the binding pocket [10]. Thus, neurotransmitter binding to the N-terminal
binding site can allosterically (remotely) control the channel gate through an evolutionarily
interconnected allosteric network [11, 12]. There are 17 subunits and isoforms of nAChRs: α1–
10, β1–4, γ, δ, and ε [1, 2, 13]. The pentameric receptor can have five identical (such as in α7
nAChR) or different (such as in α4β2 nAChR) subunits in a receptor. In the mammalian brain,
the major subtypes are heteromeric α4β2 and homomeric α7 nAChRs [2].
Homomeric α7 nAChR is widely distributed in the CNS and autonomic ganglia. It has
much higher calcium permeability than other subtypes of nAChRs [1]. In addition to excit-
atory synaptic transmission, α7 nAChR also plays an important role in transmitter release
[14], neurite growth [15], neuronal survival and apoptosis[16] and neuronal plasticity [17].
Dysfunction of α7 nAChR is associated several neurological and psychiatric disorders, such as
schizophrenia [18]. In addition, α7 nAChR gene deletion is associated with seizures and mental
retardation [19, 20].
Transcript of α7 nAChR subunit is also found in immune cells, especially in macrophages
in peripheral blood and microglia cells in the CNS [21]. In fact, nicotine has anti-inflammatory
effects, which can be blocked by α7 selective antagonist [22]. Experimental evidence suggests
that there are cholinergic anti-inflammatory pathways in peripheral and CNS via α7 nAChR
expressed on macrophage or microglia [23, 24]. These studies suggest the essential role of α7
nAChR in inhibiting cytokine synthesis by the cholinergic anti-inflammatory pathway. A more
recent study suggests that the α7 nAChR mediates the inhibition of T cell function through the
regulatory T cells [25].
Single Nucleotide Polymorphisms (SNPs) are single base variations of the DNA sequence
among individuals of the same species [26]. In the coding region of exons, a SNP can cause
missense mutations, which result in substitution of an amino acid residue at the protein level,
which may have impact on protein expression and/or function.
The SNP database [27], dbSNP, in the National Center for Biotechnology Information
(NCBI) listed 55 SNPs causing missense mutations of the human α7nAChR. Mapping these
mutations in the 3D structure of the α7 nAChR subunit homology model, we identified 14
α7nAChR SNPs that cause missense mutations in the agonist binding loops or the coupling
region between amino terminal domain and transmembrane domain (Fig 1). Specifically, these
mutants are located in the binding loop A (Y93C), loop C (C191Y, K192R, and D197N), loop
D (W55G); coupling loop 2 (N47D), loop 9 (N171S and E173K), pre-M1 (R205C, R205H, and
R206C), and extracellular end of M1 (Y211C, G212V and G212S). In this study, we character-
ized the functional impact of these 14 mutants for the neurotransmitter acetylcholine, and
smoking related agonist nicotine. These SNPs and corresponding mutations are listed in
Table 1. It should be pointed out that although in this study we selected the mutants in the
binding site and coupling region, we cannot exclude possibility that mutations in other part of
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the receptor can influence channel function. As demonstrated by single channel studies to map
gating energy changes upon mutagenic perturbation in multiple domains, although sources of
gating energy are mainly from the binding loops C, B, and A, other part of the receptor can
also influence channel gating, but to a lesser extent. [28, 29].
Materials and Methods
Mutagenesis and cRNA Preparation
The cDNA encoding wild type human α7 nAChR subunit was cloned into pGEMHE oocyte
expression vector with T7 orientation. The mutations were made with the PCR-based Quik-
Change method of the site-directed mutagenesis (Stratagene, Hercules, CA, USA) with Phu-
sion DNA polymerase (New England Biolab, Ipswich, MA). The mutations were confirmed by
Fig 1. Location of 14 mutations in the α7 nAChR receptor. A: The residues with the mutations in the
binding region (loops A (TYR93), and C (CYS191, LYS192, ASP197) of the principal side of a binding pocket,
and D (TRP55) of the complementary side of the neighboring binding pocket); B, The residues with the
mutations in the coupling region (loop 2 (ASN47), loop 9 (ASN171 and GLU173), pre-M1 (ARG205 and
ARG206) and M1 (TYR211 and GLY212).
doi:10.1371/journal.pone.0137588.g001
Table 1. List of the SNPs of the human α7 nAChR in this study.
SNP name Missense mutation Numbering w/o signal peptide Location in the receptor
rs201473594 N69D N47D Loop 2 (coupling)
rs12899798 W77G W55G Loop D (binding)
rs200908085 Y115C Y93C Loop A (binding)
rs201108331 N193S N171S Loop 9 (coupling)
rs201210785 E195K E173K Loop 9 (coupling)
rs200236230 C213Y C191Y Loop C (binding)
rs143167432 K214R K192R Loop C (binding)
rs377100778 D219N D197N Loop C (binding)
rs140316734 R227C R205C Pre-M1 (coupling)
rs138222088 R227H R205H Pre-M1 (coupling)
rs201224804 R228C R206C Pre-M1 (coupling)
rs142728508 Y233C Y211C M1 (coupling)
rs201524804 G234S G212S M1 (coupling)
rs377388459 G234V G212V M1 (coupling)
doi:10.1371/journal.pone.0137588.t001
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automated DNA sequencing of the entire coding region. The wild type and mutant cDNAs
were amplified by PCR with Phusion DNA polymerase and M13 forward and reverse primers,
and used as the DNA templates for cRNA synthesis. The cRNAs were transcribed by standard
in vitro transcription using T7 RNA polymerase. After degradation of the DNA template by
RNase-free DNase I, the cRNAs were purified and resuspended in diethyl pyrocarbonate
(DEPC)-treated water. cRNA yield and integrity were examined with an Eppendorf BioPhot-
ometer and a 1% agarose gel.
Oocyte preparation and injection
Oocytes were harvested from female Xenopus laevis (Xenopus I, Ann Arbor, MI, USA), using
the protocol "Xenopus Care and Use" approved by the Institutional Animal Care and Use
Committee of the St. Joseph's Hospital and Medical Center for this study. Briefly, the frog was
anesthetized by 0.2% MS-222. The ovarian lobes were surgically removed and placed in the
incubation solution consisting of (in mM) 82.5 NaCl, 2.5 KCl, 1 MgCl2, 1 CaCl2, 1 Na2HPO4,
0.6 theophylline, 2.5 sodium pyruvate, and 5 HEPES; 50 U/ml penicillin, and 50 μg/ml strepto-
mycin, pH 7.5. The frog was given analgesic xylazine hydrochloride (10mg/kg, ip) and antibi-
otic gentamicin (ip, 3mg/kg) after surgery, and then allowed to recover from the surgery before
being returned to the incubation tank. The animals were euthanized under anesthesia with
MS-222 after the third surgery. The ovarian lobes were cut into small pieces and digested with
1 Wunsch unit/ml liberase blendzyme 3 (Roche Applied Science, Indianapolis, IN, USA) with
constant stirring at room temperature for 1.5–2 hours. The dispersed oocytes were thoroughly
rinsed with the above solution. The stage VI oocytes were selected and incubated at 16°C before
injection. Micropipettes for injection were pulled from borosilicate glass on a Sutter P87 hori-
zontal puller, and the tips were cut with forceps to40 μm in diameter. The cRNA was drawn
up into the micropipette and injected into oocytes with a Nanoject micro-injection system
(Drummond, Broomall, PA, USA) at a total volume of 20~60 nl.
Two-electrode voltage-clamp
Two to 4 days after injection, the oocytes expressing the wild type or mutant receptors were
placed in a custom made small volume chamber with continuous perfusion with the calcium-
free oocyte Ringer’s solution, which consisted of (in mM) 92.5 NaCl, 2.5 KCl, 1.8 BaCl2, and
5 HEPES, pH 7.5. The chamber was grounded through an agar KCl bridge. The oocytes were
voltage-clamped at-70 mV to measure ACh-, nicotine-, or 4BP-TQS-induced currents using an
AxoClamp 900A amplifier (Molecular Devices, Sunnyvale, CA, USA). The current signal was
filtered at 50 Hz with the built-in 4 pole low-pass Bessel filter in the AxoClamp 900A and digi-
tized at 100 Hz with Digidata1440A (Molecular Devices).
Drug Preparation
Acetylcholine chloride and nicotine (SigmaAldrich, St. Louis, MO, USA) PNU-120596 and
4BP-TQS (Tocris, Bristol, UK), atropine (SigmaAldrich) stock solutions were prepared from
the solid and stored at-20°C in aliquots. Working concentrations of these drugs were prepared
from stock solutions immediately before use.
Data Analysis
The peak current and net charge of the ACh-induced current were measured using Clamp-
fit10.3. The peak current was measured relative the average baseline within 1 second before
ACh application switching. The net charge (the area under the curve) was measured with the
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start point 0.5 second after the pinch valve switching (~0.5 second before inward current ris-
ing) to 4 seconds later, when the fast decay phase of the currents induced by all concentrations
of ACh was essentially completed for the wild type and mutants, using the average baseline
within 1 second before agonist application switching. The concentration-response relationship
of the agonist-induced current or charge in recombinant nAChRs was least-squares fit to a Hill
equation with GraphPad Prism 6.0 (GraphPad Software, Inc, La Jolla, CA) to derive the EC50
(the agonist concentration required for inducing a half maximal change), Hill coefficient (the
slope factor), and maximum current, which was then used to normalize the concentration-
response curve from individual oocytes. The average of the normalized currents or charges
for each agonist concentration was used to plot the data. All the data were presented as
mean ± SEM (standard error). Statistical comparisons for logEC50s, agonist-induced currents
at a saturation concentration, or allosteric modulator rescued currents between wild type/blank
control and multiple mutants were performed with one way ANOVA, or two-sided grouped t-
test for two group comparison. Correlation between two parameters was performed by linear
regression analysis in Prism6.0.
Homology Modeling
The homology model of the human α7nAChR subunit was made with ICM Pro 3.7–2C (Mol-
Soft, San Diego, CA) using chain A of the EM structure of Torpedo nicotinic receptor (PDBID:
2BG9 chain A) as the template for Fig 1. The resulting models were used to map the SNPs in
the 3D structure using Discovery Studio 4.0 Visualizer (Biovia, San Diego, CA). The same soft-
ware was also used to present the crystal structures of acetylcholine binding protein (AChBP)
with ACh or nicotine in the binding pocket (PDBID: ACh binding with AChBP: 3WIP, nico-
tine binding with AChBP: 1UW6).
Results
Influence of mutations on the currents induced by ACh and nicotine
To test the impact of the 13 mutants (excluding W55G, which was tested in a separate experi-
ment, as it was reported in the 2010 Society for Neuroscience Annual Meeting), we injected the
same amount of cRNAs of the wild type and 13 mutants into Xenopus oocytes and tested recep-
tor function with 3.16 mM ACh, a saturation concentration of the wild type α7 nAChR. Fig 2A
shows the average currents induced by ACh for each construct. Note that except for two G212
mutants and K192R, all the remaining mutants exhibited reduced currents when compared to
the wild type. Among them, R205C, R205H, N171S, and N47D mutants exhibited 3.5- to
5-fold reduction. But their current levels were still significantly higher than the un-injected
control. Interestingly, Y93C, E173K, D197N, C191Y, R206C, and Y211C were nearly insensi-
tive to 3.16 mM ACh. The very low ACh-induced currents are likely due to muscarinic receptor
activation by the high ACh concentration, despite the presence of 1μM atropine, because these
small currents were not statistically different from the current induced by 3.16 mM ACh in the
un-injected oocytes. Thus, these mutants are essentially nonfunctional. The responses to
3.16mM nicotine are also shown in Fig 2A. The current responses to nicotine for all constructs
exhibited a pattern similar to that for ACh responses. High concentration nicotine-induced
small currents in the same set of six mutants were also not significantly different from that
from the blank oocytes. Due to higher background current induced by 3.16mM nicotine in un-
injected control and lower nicotine-induced current, the nicotine-induced currents in R205C,
R205H, N171S, and N47D mutants did not reach statistical significance when compared to the
un-injected control. The mechanism for the nonspecific effect of high concentration nicotine
on the oocytes is unknown. However, we have noticed that it is oocyte batch dependent. In
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summary, out of 13 mutants tested, only three mutants showed similar current levels as the
wild type. There were four functional mutants with reduced currents, and six nonfunctional
mutants.
For the W55G mutation, our results for ACh responses were similar to a previous report by
Williams et al [30]. In addition, we also noticed that W55G mutation differentially altered the
ACh and nicotine responses. Fig 2B shows that W55G mutation dramatically increased the
Fig 2. Current responses of the wild type andmutant receptors to 3.16mMACh or nicotine with non-
injected oocyte controls. A. 13 mutants and wild type control along with un-injected oocyte control (for
nonfunctional mutants). The same amount of cRNAs for the wild type or mutant receptors was injected. On
the 3rd post-injection day, the oocytes were tested with ACh (with 1 μM atropine) or nicotine. The name of
each condition is indicated at the bottom of each bar. Each group had 8–18 oocytes from two sets of
experiments. Asterisk (*, **, or ****) represents that the difference between the wild type and each mutant
is statistically significant (P<0.05, P<0.01, or P<0.0001) in Tukey multiple comparison test of one-way
ANOVA. ♦, ♦♦ or ♦♦♦♦ represent the statistical difference with P<0.05, P<0.01, or P<0.0001 between blank
and each mutant. B. W55Gmutant and its wild type control in a separate experiment (10 oocytes each
group). ****: P<0.0001 with 2-sided grouped t-test.
doi:10.1371/journal.pone.0137588.g002
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3.16mM ACh-induced current, but dramatically decreased 3.16mM nicotine induced current.
We will discuss the potential mechanism for this difference later.
Concentration-response relationships of functional mutants and current
kinetics
To further characterize sensitivity of the functional mutants, we performed concentration
response analysis. Fig 3A and 3B shows that 7 functional mutants were similar to, or only
slightly deviated from, the wild type in their ACh sensitivity. Their pEC50s (negative log of the
concentration required to activated 50% charge) are plotted in Fig 3C. Note that, only N171S
mutant had slightly lower sensitivity than the wild type statistically significant with charge
analysis. For their current decay kinetics, there was no obvious difference that we can resolve
with our recordings. For nicotine concentration-response, because high concentration of nico-
tine could induce small currents in un-injected oocytes, we could not get clean concentration-
response relationships for these mutants (data not shown). In contrast, the W55G mutant
exhibited larger sensitivity shift with a 6.5-fold reduction of the receptor sensitivity to its natu-
ral agonist, ACh (Fig 4A), and a 12-fold reduction for nicotine sensitivity (Fig 4B). By examin-
ing the current traces, it is also noticeable that the decay rate of the ACh-induced current is
slower in W55G mutant, similar to a previous finding [30]. In addition, it is obvious that the
kinetics of the nicotine-induced current in W55G mutant is much slower than that in the wild
type. Fig 4 also demonstrates that 3.16mM nicotine used in Fig 2B is near saturation concentra-
tion for both the wild type andW55G mutant, whereas 3.16mM ACh is a saturation concentra-
tion for the wild type, but is at about EC80 for W55G. It means that the maximum response of
W55G to ACh should be higher than the 3.16mM ACh-induced current. Thus, we can also
conclude that the W55G mutation dramatically increased ACh efficacy, but reduced nicotine
efficacy. In summary, for the functional mutants, W55G altered the sensitivity to both ACh
and nicotine in the same direction and to a similar extent. N171S is the only other functional
mutant with a slight decrease in ACh sensitivity.
Rescuing nonfunctional mutants by positive allosteric modulator
As mentioned above, we have identified 6 mutants, which were essentially non-responsive to
3.16 mM ACh. This non-responsiveness may indicate that the mutant receptors are not func-
tional despite surface expression in the cell membrane. Alternatively, the mutations may influ-
ence surface expression or assembly of the receptor. Since these non-responsive mutants are
with the mutations in the binding site or coupling region, it is likely that surface expression is
normal but function is impaired. These two possibilities will be differentiated by the rescuing
effect of positive allosteric modulators or allosteric agonists.
The positive allosteric modulators (PAM) of α7 nAChR bind to the allosteric site in N-ter-
minal domain or transmembrane domain to facilitate channel opening [31–33]. They have
promising therapeutic potential [34]. The PAMs presumably reduce the energy barrier for
channel opening. In fact, one PAM, PNU-120596, has been used to reveal function of some α7
nAChR silent agonists [35, 36]. Thus, it is possible that co-application of this PAM can rescue
the nonfunctional mutant receptor. To test this hypothesis, we co-applied PNU-120596 with
ACh or nicotine to all six non-responsive mutants. Indeed, some of the nonresponsive mutants
became functional in the presence of PNU-120596. Fig 5A shows that PNU-120596 rescued
ACh response in Y93C and R211C mutants, but not for the other 4 mutants. The rescue of the
two mutants suggests that the mutants have surface expression, but their function is impaired
due to mutation in the binding site in case of Y93C or the mutation in the coupling region in
case of R211C. Interestingly, PNU-120596 rescued one more mutant (C191Y) in addition to
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Y93C and R211C for nicotine response. The nicotine response of another loop C mutant,
D197N, could also be partially rescued. Although it was not significantly different from the
blank control in initial ANOVA test, if we remove those groups with larger means (probably
contributing larger variations to mask the groups with smaller values) in the ANOVA test,
then it was significantly different from the blank control (P<0.0001). It was further confirmed
Fig 3. ACh concentration-response for most of the functional mutants. A. Representative current traces
induced by ACh for the wild type and mutant receptors with the concentrations indicated. B. Averaged and
normalized concentration-responses of charge (6–8 oocytes each group). Lines are nonlinear least squares
fits of the normalized averages of the responses to the Hill equation.C. Bar graph of the pEC50 values
(negative logEC50s) derived from B. ***: P<0.001 when compared to theWT value.
doi:10.1371/journal.pone.0137588.g003
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by the concentration response (see Fig 6). However, the function of E173K and R206C mutants
for either ACh or nicotine could not be rescued by PNU-120596.
Since the nonfunctional mutants have mutations in the orthosteric binding site or the cou-
pling region between N-terminal domain and transmembrane domain, it is likely that these
mutations do not influence the activation by an allosteric agonist. 4BP-TQS is a structural ana-
log of an a7nAChR PAM, TQS. In addition to the PAM effect, it can also directly activate
α7nAChR by binding to an allosteric site located in the second transmembrane, channel-lining,
domain [37]. Fig 5B shows that 4BP-TQS directly activated 2 binding site mutants Y93C and
C191Y, and 1 mutant in M1 (Y211C). Although the difference between Y93C and blank con-
trol did not reach statistical significance with ANOVA, it had the trend. The concentration
response of 4BP-TQS for this mutant further supports that it could be activated by 4BP-TQS
(see Fig 7). However, 4BP-TQS alone failed to activate E173K and D197N mutants, although
both mutations are located in the N-terminal domain.
Since 4BP-TQS is also a PAM, it is also possible that it can rescue more nonfunctional
mutants in the presence of an orthosteric agonist. Fig 5C shows that in the presence of ACh or
nicotine, 4BP-TQS rescued more mutants than PNU-120596. Note that 4BP-TQS also showed
a trend to rescue the ACh and nicotine effects on E173K and D197N mutant. Although the res-
cued currents did not reach statistical significance in initial ANOVA test, if we remove the
groups with larger means (probably contributing larger variations to mask the groups with
Fig 4. Concentration-responses of W55Gmutant to ACh and nicotine. A. Concentration responses of the wild type andW55G to ACh. Top: raw current
traces; bottom: normalized and averaged currents. Lines are least-squares fit of the data to the Hill equation. The resulting EC50 for ACh in the wild type
receptor was 210.5±24.3 μM, and the EC50 for W55Gmutant was 1375.3±130.5 μM (N = 5). B. Concentration responses of the wild type andW55G to
nicotine. Top: raw current traces; bottom: normalized and averaged currents. Lines are least-squares fit of the data to the Hill equation. The resulting EC50
values for nicotine were 43.6±4.8 μM and 530.40±12.91 μM for the wild type and mutant receptor respectively (N = 5).
doi:10.1371/journal.pone.0137588.g004
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Fig 5. Agonist-responses for the nonfunctional mutants in the presence of a PAM or agonist-PAM. A.
Co-application of 31.6 μMPNU-120596 with 200 μMACh or nicotine rescued the receptor functions for some
of the nonfunctional mutants. The same amount of cRNA was injected for each group, and recordings were
performed after 3 days in 9–19 oocytes for each group). The bar graph represents the average currents
rescued by PNU-120596. In case of the wild type, the current represents the rescued current from
desensitization. B, Direct activation of nonfunctional mutants by 4BP-TQS. The same amount of cRNA was
injected for each group, and recordings were performed after 3 days in 10–17 oocytes in each group). C, Co-
application of 4BP-TQS with ACh or nicotine rescued more mutants. The same amount of cRNA was injected
for each group, and recordings were performed after 3 days in 9–19 oocytes in each group. Asterisk (****)
represents that the difference between the wild type and each mutant is statistically significant (P<0.0001) in
Tukey multiple comparison test of one-way ANOVA. ♦♦, ♦♦♦, or ♦♦♦♦ represent the difference between
blank and each mutant with statistical significance (P<0.01, P<0.001, or P<0.0001).
doi:10.1371/journal.pone.0137588.g005
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smaller values) in the ANOVA test, then the rescued currents in these two mutants for both
ACh and nicotine were significantly higher than the blank control (P<0.0001). The rescuing
effects in these mutants were further confirmed by their concentration responses of these
Fig 6. PNU120596 concentration-response for the rescued nonfunctional mutants with a fixed ACh or nicotine concentration. A. Representative
current traces induced by increasing concentration of PNU-120596 in the presence of 200 μMACh.B. Normalized and averaged (each group had at least 6
oocytes) current responses to ACh from A. Lines are nonlinear least squares fits of the normalized averages of the responses to the Hill equation. The
derived EC50 values from individual fits are listed in Table 2. C. Representative current traces induced by increasing concentration of PNU-120596 in the
presence of 200 μM nicotine. D. Normalized and averaged current responses (each group had at least 6 oocytes) to ACh from C. The derived EC50 values
from individual fits are listed in Table 2.
doi:10.1371/journal.pone.0137588.g006
Table 2. EC50 values for PNU-120596 with the fixed concentration of ACh/nicotine for the rescued
mutants.
Mutant name EC50 (μM) with ACh EC50 (μM) with nicotine
WT 1.15±0.09 0.11±0.01
Y93C 2.09±0.10 5.22±0.62
C191Y ND 0.60±0.05
D197N ND 3.22±0.37
Y211C 2.91±0.20 0.67±0.10
ND: not detectable
doi:10.1371/journal.pone.0137588.t002
Functional Impact of α7 nAChR SNPs
PLOSONE | DOI:10.1371/journal.pone.0137588 September 4, 2015 11 / 22
mutants (Fig 8). However, the response to ACh or nicotine in the presence of 4BP-TQS for
R206C mutant was essentially the same as the blank control.
Concentration-response of the rescuing effect for nonfunctional mutants
To address whether the rescuing effect is concentration-dependent, we performed experiments
with a fixed ACh or nicotine concentration in the absence and presence of increasing concen-
tration of PNU-120596. Fig 6A and 6B show that with the fixed ACh concentration at 200 μM,
PNU-120596 rescued the mutant receptor function concentration-dependently. Compared to
the wild type receptor (rescued current from desensitization), 1.8 or 2.5-fold higher PNU-
120596 concentrations were needed to rescue two mutant receptors. PNU-120596 rescued
nicotine response in two more mutants C191Y and D197N, in addition to Y93C and R211C
(Fig 6C and 6D). However, since the wild type PNU-120596 sensitivity is dramatically shifted
to the left in the presence of a constant concentration of nicotine, the mutants showed larger
Fig 7. Concentration response of 4BP-TQS direct activation of the wild type control and Y93C, C191Y,
and Y211Cmutants. A, Representative current traces induced by increasing concentration of 4BP-TQS. B.
Normalized and averaged current responses to 4BP-TQS from A. Lines are nonlinear least squares fits of the
normalized averages of the responses to the Hill equation. The resulting EC50 values were 5.54±0.31, 8.21
±1.03, 13.73±1.73, and 4.23±0.30 μM for the wild type control and Y93C, C191Y, and Y211Cmutants
respectively (n = 6 for each group).
doi:10.1371/journal.pone.0137588.g007
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difference (6-, 6-, 31-, 50-fold less sensitive than the wild type for mutants C191Y, R211C,
D197N, and Y93C, respectively) from the wild type (rescued desensitization).
The concentration responses of 4BP-TQS direct activation of Y93C, C191Y, and Y211C are
shown in Fig 7. Despite of non-responsiveness to ACh, the sensitivity of these three mutants to
4BP-TQS were not dramatically deviated from the wild type (1.5-, 2.5-, or 0.8-fold difference
when compared to the wild type).
Fig 8. 4BP-TQS concentration-response for the rescued nonfunctional mutants with a fixed ACh or nicotine concentration. A. Representative
current traces induced by increasing concentration of 4BP-TQS in the presence of 200 μMACh. B. Normalized and averaged (each group had 5–6 oocytes)
current responses from A. Lines are nonlinear least squares fits of the normalized averages of the responses to the Hill equation. The derived EC50 values
from individual fits are listed in Table 3. C. Representative current traces induced by increasing concentration of 4BP-TQS in the presence of 200 μM
nicotine.D. Normalized and averaged current responses (each group had 5–6 oocytes) from C. The derived EC50 values from individual fits are listed in
Table 3.
doi:10.1371/journal.pone.0137588.g008
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The rescuing effects of 4BP-TQS in the presence of an orthosteric agonist for five nonfunc-
tional mutants were also concentration dependent. Fig 8A and 8B show the rescuing effect of
4BP-TQS for ACh responses of these mutants. Compared to the wild type receptor, 3-, 12-,
10-, 14-, or 21-fold higher 4BP-TQS concentration are required to rescue Y93C, E173K,
Fig 9. Coexpression of wild type and nonfunctional mutant. The same amount of cRNAs encoding the wild type or wild type plus mutant (in 1:1 ratio)
were injected into Xenopus oocytes, and recorded with two electrode voltage clamp for ACh-induced current after 3 days of injection. A. Peak current induced
by 3.16mM ACh for all groups on the 3 post-injection day. "****": P<0.0001. Each group had at least 16 oocytes.B. Averaged concentration response
relationships of the wild type and wild type plus mutant as indicated. Each group is the average of six oocyte data.C. EC50 values were derived by fitting
individual concentration-response curves in B. pEC50 values (negative logEC50) are used to plot the data. ("**", “***”, “****”: p<0.01, P<0.001, or
P<0.0001).D. Linear regression analysis for the relationship between Hill slope and LogEC50.
doi:10.1371/journal.pone.0137588.g009
Table 3. EC50 values for 4BP-TQSwith the fixed concentration of ACh/nicotine for the rescued
mutants.
Mutant name EC50 (μM) with ACh EC50 (μM) with nicotine
WT 0.27±0.04 0.19±0.03
Y93C 0.92±0.08 1.07±0.05
E173K 3.11±0.19 >31.6
C191Y 2.57±0.50 0.44±0.06
D197N 3.85±0.34 1.29±0.05
Y211C 5.50±2.74 0.70±0.14
doi:10.1371/journal.pone.0137588.t003
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C191Y, D197N, and Y211C mutants respectively, Note that unlike other mutants, the rescued
current in E173K exhibited a relatively rapid desensitization, although the shift of EC50 for
4BP-TQS was not the highest among these five mutants. 4BP-TQS also rescued nicotine
responses of these five mutants as shown in Fig 8C and 8D. While Y93C, C191Y, D197N and
Y211C only showed moderate decrease (6-, 2-, 7-, 4-fold respectively) in sensitivity to
4BP-TQS in the presence of nicotine, E173K required greater than 163-fold higher concentra-
tion of 4BP-TQS to rescue its function. This is in contrast to a 12-fold increase in EC50 for
4BP-TQS with ACh. Similar to the rescuing effect with ACh, the rescued current of this mutant
also exhibited rapid desensitization.
Coexpression of nonfunctional mutants with the wild type
Up to this point, our testing has been restricted to independent mutant receptors, which is
equivalent to the homozygote condition. However, in real life, the frequency of heterozygote
carriers is much higher than that of homozygote individuals. Thus, it is equally important to
test whether heterozygote mimicking condition (coexpression of mutant and wild type) has
impact on the receptor function. Fig 9A shows the currents induced by 3.16mM ACh for the 6
nonfunctional mutants separately coexpressed with the wild type. Coexpression of each mutant
with the wild type was clearly functional. However, except for Y211C coexpression, all the
other nonfunctional mutant coexpressions resulted in reduced ACh-induced current. The con-
centration-response relationships of the wild type and coexpressed mutants are plotted in
Fig 9B. It seems that all mutant coexpressions could slightly reduce receptor sensitivity, since
all mutant coexpressions show small rightward shift in their concentration-response relation-
ships. By fitting the data to the Hill equation, we derived EC50 values for these concentration-
response relationships. Fig 9C is the bar graph for pEC50 (negative log). Except for E173K coex-
pression, all the other mutant coexpressions exhibited slightly shifted EC50 values from the
wild type receptor alone with statistical significance. Interestingly, we have also noticed that
coexpression of the mutants with the wild type also reduced Hill coefficients to different
extents. The mutant coexpressions with lower Hill coefficients tended to have larger EC50 shifts
(Fig 9D). We will discuss this linear relationship later.
Discussion
There are 55 SNPs causing missense mutations in the coding region of the human α7 nAChR
gene in the NCBI SNP database. In this study, we selected and characterized 14 SNPs causing
missense mutations in the agonist binding region and the coupling region between the amino-
terminal domain and the channel gate in the transmembrane domain. In the oocyte expression
system, we demonstrate that 6 out of 14 mutations made the receptors unresponsive to ACh
and or nicotine in this expression system. Among remaining 8 mutants, 4 of them had reduced
current expression, and one had a dramatic increase in ACh response but a dramatic decrease
in nicotine response. Interestingly, some nonfunctional mutations could be rescued by α7
nAChR PAM, PNU-120596 or agonist-PAM, 4BP-TQS. Finally, when nonfunctional mutants
coexpressed with the wild type, they could modify the receptor function in expression level or
agonist sensitivity, suggesting a potential impact of these 6 SNPs on synaptic transmission even
in heterozygous condition.
Impact of the mutations on current level
Among 14 mutants tested, we found 4 of them showed reduced maximal whole-cell current
expression and 6 of them were totally nonfunctional in the Xenopus oocyte system. Interest-
ingly, W55G mutation dramatically increased ACh-induced current. Thus, except for two
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mutants (G212S and G212V) in the extracellular end of M1 domain and one conserved mutant
in binding loop C, K192R, all the other mutants in the binding domain and coupling region
exhibited different extent of alteration in whole-cell current level. Interestingly, while most of
the mutants exhibited similar changes in ACh and nicotine responses, the W55G mutant
exhibited an opposite change in ACh and nicotine response. Alteration of whole cell current
could be due to a change in the number of channels expressed in the plasma membrane. Alter-
natively, it may result from the altered channel opening probability (gating efficiency) or
changes in single channel conductance. In addition, it is also possible that the change in current
level could be due to alteration in receptor channel kinetics, such as desensitization.
For nonfunctional mutants, the question is whether they are expressed on the cell surface.
The function of the Y93C, E173C, C191Y, D197N, and Y211C could be rescued in the presence
of a PAM for α7 nAChR, suggesting that they are expressed on the cell surface, but their func-
tion is disrupted by the mutations. Y93C and C191Y are the mutations in the binding site
located in binding loop A and loop C. These two mutations most likely decrease the binding
energy to such an extent that the channel cannot be opened upon agonist binding. However, in
the presence of the positive allosteric modulator PNU-120596, the energy barrier for channel
opening is reduced. Thus, the agonist can reopen the channel despite of the reduced binding
energy for these mutant channels. Tyr93 is essential for orthosteric activation, and the muta-
tion of this residue to cysteine makes the receptor insensitive to ACh, but still can be activated
by an allosteric agonist [38]. Our results with 4BP-TQS direct activation of Y93C are consistent
with that finding. Interestingly, for the C191Y mutant, rescuing effects of the PAM with ACh
or nicotine are different. PNU-120596 could only rescue the nicotine effect but not the ACh
effect. This phenomenon suggests that the binding energy loss for ACh is much higher than
Fig 10. Different interactions of ACh and nicotine with the AChBP binding residues. A. The binding pocket between chain A and chain B of the AChBP
co-crystalized with ACh (PBDID: 3WIP); B. The binding pocket between chain A and chain B of the AChBP co-crystalized with nicotine (PBDID: 1UW6). The
residues of Cys191 and Trp55 in the human α7nAChR are labeled next to their homologous residues in the AChBP. Arrows indicate different interactions.
doi:10.1371/journal.pone.0137588.g010
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that for nicotine in this mutant. In the crystal structures of ACh binding protein (AChBP), a
soluble protein homologous to the amino-terminal domain of nicotinic receptor, the homolo-
gous cysteine (CYS188) does not form the disulfide bridge with the neighboring cysteine
(CYS187) when ACh bound to the receptor, but this cysteine residue can coordinate with
another binding residue (TYR192) in the same loop C to interact with ACh (Fig 10A, [39]).
Note that in the same pentameric structure of AChBP (3WIP chains A-E), chains A, D, E do
not have a disulfide bond, but chains B and C do have a disulfide bond. This suggests that the
receptor can adopt two different conformations when binding ACh. In contrast, when nicotine
is in the binding site, the homologous cysteine can form a disulfide bridge with the neighboring
cysteine in all five subunits of the pentameric structure and indirectly interacts with nicotine
(Fig 10B, [40]). For the Y211C mutation, it is likely that the mutation decreases the coupling
between the M1 and M2-M3 domains, the outward tilting of the latter is proposed to be the
mechanism for channel activation for this receptor family [41]. In fact, a computational study
predict that the activation pathway of this receptor family is via pre-M1 region [42]. In our
homology model, this residue is facing the beginning of M3 domain and is likely to be interact-
ing with Met261. The mutation of Y211C probably disrupts the coupling between pre-M1 to
M2-M3 domain, making the receptor nonfunctional. However, weakening of gating energy by
PN-120596 would allowed the weakened coupling to transduce the binding energy enough to
open the channel. For D197N nonfunctional mutation, the nicotine but not the ACh effect
could be partially rescued by PNU-120596. However, 4BP-TQS could partially rescue ACh and
nicotine effect. This differential effect again suggests that nicotine and acetylcholine gate the
channel differently, and PNU-120596 and 4BP-TQS modulate the channel differently. Asp197
is likely a key residue in coordinating the binding loops B and C. In fact, it forms a functionally
important triad with Tyr188 and Lys145 (loop B) [43]. The homologous residue (Asp194)
along with Lys139 (loop B) and Tyr185 in the α1 muscle type nicotinic receptor has been
shown to be functionally important triad. Dynamic interaction of this triad is an important
mechanism for channel activation [44]. For nonfunctional E173K mutant, Glu173 is located in
loop 9. It has been reported that the mutation of this residue (E173A) could completely abolish
the current, but preserve the surface expression of the mutant receptor [45]. Other mutations
of this residue have similar effects, suggesting that Glu173 is an important coupling residue.
Mutation of this residue can completely uncouple the agonist binding to the channel gating.
An alternative explanation of the PAM effect is that it makes the desensitized state conduct-
ing as proposed by Williams et al [46]. With this mechanism, the rescuable nonfunctional
mutants can directly go to desensitized state upon agonist binding. However, in the presence of
a PAMII, the desensitized channel is converted to a conducting state with different gating
kinetics and even with different single channel conductance. Thus, they lack normal activation
state, but still can be desensitized and converted to a conducting desensitized state by a PAMII.
Regardless the mechanism, functional rescue of nonfunctional channel would have potential
clinical applications.
4BP-TQS is an allosteric agonist as well as a PAM for α7nAChR. For the nonfunctional
mutations in the orthosteric binding site or coupling region, if their surface expression is
preserved, we expect that their response to 4BP-TQS direct activation through the allosteric
site in the M2 domain should be normal. Indeed, 4BP-TQS directly activated Y93C, C191Y,
and Y211C mutant receptors. The concentration response of 4BP-TQS for these mutants were
similar to that for the wild type receptor, suggesting that mutations in the binding loop C tip,
loop A, and M1 do not influence 4BP-TQS binding and function. However, in additional to
sensitivity, we have noticed that the amplitude of the 4BP-TQS-induced currents in these 3
mutants was also different. With near saturation concentration, 4BP-TQS induced-current
in Y211C had similar amplitude as the wild type. In contrast, Y93C and C191Y had the
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4BP-TQS-induced currents with significantly lower amplitude, suggesting that these mutations
may reduce the receptor surface expression. Alternatively, the mutations in the binding sites
could allosterically influence channel gating efficiency. In GABAA/C receptors, mutations of
residues in the binding loops A, B, or E created spontaneously opening channels [47, 48]. Thus,
it is possible that mutation of a residue in the binding site can have an impact on the channel
gating. Perhaps Y93C and C191Y mutations not only influence binding, but also allosterically
inhibit channel gating, resulting in lower gating efficiency by the allosteric agonist 4BP-TQS.
In contrast, Y211C has no direct effect on channel gating as reflected by the full efficacy of
4BP-TQS when compared to the wild type. Its effect on the activation by orthosteric agonist
likely due to uncoupling of the N-terminal orthosteric binding domain to the channel gating
domain. This explanation is further supported by its similar 4BP-TQS sensitivity to that of the
wild type. In comparison, the 4BP-TQS sensitivity of the Y93C and C191Y mutants were
slightly reduced. For E173K and D197N mutants, unexpectedly, they could not be activated by
4BP-TQS alone, but their function could be restored with the collaborative effort of an alloste-
ric agonist and an orthosteric agonist. Thus, the perturbation in the orthosteric binding loop C
arm (D197N) or the coupling region (E173K) not only severely impair the coupling between
the orthosteric binding site and the channel gate, but also completely abolish direct gating by
allosteric agonist. The non-rescuable mutants could influence receptor assembly or might have
a larger influence in binding or coupling energy. The conserved arginine at the middle position
of the pre-M1 RRR motif of nicotinic receptor subunits is required for the transport of assem-
bled α7 nAChR to the cell surface [49]. Thus, the corresponding R206C mutation would likely
prevent surface expression of the receptor, most probably by disrupting interactions between
pre-M1, loop2 and M2-M3 linker as suggested by molecular dynamics simulation in α7
nAChR [50] or experimental evidence in other subunits [51].
For the functional W55G mutant, our findings of its impact on ACh response are consistent
with previous reports [30, 52]. In addition, our observation of differential impact of this mutant
on ACh and nicotine efficacy is interesting. By examining the crystal structures of AChBP with
ACh or nicotine, we found that nicotine can directly interact with TRP55 through a Pi-Alkyl
interaction (Fig 10B). In contrast, ACh does not directly interact with TRP55 (Fig 10A). That
could be an important mechanism for the differential impact of the mutation on the efficacy of
ACh or nicotine
Heterozygote mimicking expression for nonfunctional mutants
The frequencies of occurrence for the SNPs tested here are not determined, but they are likely
to be relatively low. Thus, the homozygote individuals carrying these SNPs should be relatively
rare. However, the heterozygous carriers of these mutations should be more frequent. To deter-
mine whether these nonfunctional mutants can influence the receptor function in heterozygote
situation, we coexpressed the nonfunctional mutants (one at a time) with the wild type recep-
tor. Our results (Fig 9) demonstrated that except for Y211C, other 5 nonfunctional mutant
coexpressions with the wild type significantly decreased the maximal current when compared
to the wild type subunit. The highest reduction of current was found in the Y93C coexpression,
with 3.9-fold change. The fold change in remaining 4 groups were 2.2, 2.7, 1.6, and 2.0 for
E173K, C191Y, D197N, and R206C. Thus, it is likely that the heterozygote individuals with
these mutations have the reduced α7 nAChR function. Notably, despite only half of the
amount of the wild type cRNA injected in Y211C mutant coexpression condition, the maxi-
mum current levels were not significantly different from the wild type. For R206C, since it is
likely that the mutation can influence surface expression, the mutant subunit may not be able
to co-assemble with the wild type subunit. Alternatively, it may get co-assembled with the wild
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type subunits with a relatively low efficiency. Incorporation of this mutant subunit into the
receptor may also influence channel function as demonstrated in Fig 9A–9C. Y93C and C191Y
are located in the binding site. Incorporation of these mutant subunit into the captor would
reduce number of binding sites in a receptor. Although at single channel level, it has been dem-
onstrated that one binding is enough to elicit full response in α7 nAChR[53], when the number
of functional binding sites is reduced in a single receptor, the chance for the receptor to get a
single binding for a given concentration of an agonist at any time would be reduced. This can
clearly influence the receptor concentration response to an agonist. Thus, receptors with differ-
ent number of functional binding sites would have slightly different sensitivities to an agonist.
The mixed population of the receptors with slightly different agonist sensitivity can result in
apparent shallow Hill slope.
Influence of E173K and D197N coexpression on the channel function likely through their
influence in coupling between agonist binding to channel gating. For the ACh concentration-
response relationship, all the receptors coexpressed with a nonfunctional mutant tend to be
shifted to the right slightly and with a shallower Hill slope. Interestingly, the increase in EC50
(in log scale) is highly correlated to the decrease in Hill coefficient. This phenomenon suggests
that co-assembly of the nonfunctional mutant subunit with wild type subunit (with different
subunit stoichiometries) can result in functional channels with slightly reduced sensitivity. In
this case, the difference in agonist sensitivity between all wild type and mutant containing
receptors could be relatively small, so that different sensitivity components cannot be resolved,
resulting in a shallow Hill slope when the data were fitted with the single Hill equation. How-
ever, the multiple sensitivity mixture can be recognized by the reduced Hill coefficient (espe-
cially when it is below unity).
Finally, although most of the SNPs we tested have been validated by multiple independent
submissions to refSNP cluster, only 6 of them have been validated by the 1000 Genome
Sequencing Project with the second generation of haplotype map (HapMapII). Another SNP
has been validated by HapMap project. It should be kept in mind that except for the SNPs caus-
ing mutations of D47N and W55G, the remaining SNPs are located in a region (exons 5–10)
that is nearly identical (with only 1 base difference) to that in CHRFAM7A gene with the par-
tial duplication of the CHRNA7 gene. Thus, it is possible that some of the α7 SNPs could be
the SNPs from CHRFAM7A gene, but mistakenly placed in the CHRNA7 SNPs. They need to
be confirmed by haplotyping or other means in the future.
In summary, in this study, we have identified 11 α7 nAChR SNPs in the agonist binding
and coupling regions that have a functional impact on the receptor. Among them, 4 SNPs were
functional but with reduced current expression, 1 with increased ACh-induced current, but
decreased nicotine-induced current expression, and 6 SNPs were nonfunctional. Among the
functional SNPs, two exhibited slightly reduced sensitivity to ACh. Interestingly, 5 nonfunc-
tional mutants can be rescued by the α7 nAChR positive allosteric modulator, PNU-120596
and/or 4BP-TQS. Nonfunctional mutants also influenced receptor function when coexpressed
with the wild type in the heterozygote mimic condition. These changes of the receptor proper-
ties by the mutations would have potential impact on physiological function of the α7nAChR-
mediated cholinergic synaptic transmission and anti-inflammatory effects. It would be interest-
ing to see whether these abnormalities of receptor function can be correlated to cognitive func-
tional differences or to an individual's anti-inflammatory ability in the future studies with
genome wide association or knockin animal models. In addition, rescuing the nonfunctional
mutants could provide a novel way to treat the related disorders.
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